Pluxee: Sharp Decline at Opening Following UBS's Downgrade to Sell

UBS Shifts from Neutral to Sell Targeting 10 Euros

UBS has changed its recommendation from neutral to sell, targeting 10 euros, representing a 10.4% decrease from this Friday's opening price. This downgrade follows a series of negative adjustments by analysts over several months. Alphavalue had already lowered its price target from 29.40 euros to 21 euros in mid-January, while Morgan Stanley reduced it from 23 to 21 euros in December. Technically, the stock is trading below all its moving averages: 13.07 euros for the 50-day moving average and 16.67 euros for the 200-day moving average, confirming a bearish trend across all time horizons. The RSI at 33 points indicates significant weakness, close to the oversold zone at 30, suggesting buyer exhaustion. The current price of 11.15 euros is slightly below the technical support level of 11.21 euros, with the next resistance set at 13.41 euros, a 20% difference.

Company Posts Q1 Revenue of 308 Million Euros, Up 9% Organically

In early January, the group reported a first-quarter revenue of 308 million euros for fiscal year 2026, marking a 9% organic growth and confirming its revised annual targets. However, this performance came after Pluxee had to lower its expectations for the year in November, following the reform of the Worker's Food Program in Brazil, its main market. The group now anticipates stable total revenue, as opposed to the high growth previously expected. Brazilian regulatory measures are expected to continue affecting financial results in the first half of fiscal 2027, with management predicting a return to a sustainable growth trajectory starting in the second half of 2027. Despite this revision, the analysts' consensus maintains an average target of 19.17 euros, implying a substantial theoretical upside potential compared to current levels. The stock has shown a catastrophic annual performance of -50.06%, with a decline of 33.67% over three months.